KR20200120465A - Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution - Google Patents
Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution Download PDFInfo
- Publication number
- KR20200120465A KR20200120465A KR1020190099546A KR20190099546A KR20200120465A KR 20200120465 A KR20200120465 A KR 20200120465A KR 1020190099546 A KR1020190099546 A KR 1020190099546A KR 20190099546 A KR20190099546 A KR 20190099546A KR 20200120465 A KR20200120465 A KR 20200120465A
- Authority
- KR
- South Korea
- Prior art keywords
- liver
- composition
- hydrogen
- hot water
- dried powder
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 206010019133 Hangover Diseases 0.000 title claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract description 66
- 206010067125 Liver injury Diseases 0.000 title abstract description 13
- 231100000234 hepatic damage Toxicity 0.000 title abstract description 13
- 230000008818 liver damage Effects 0.000 title abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 44
- 239000001257 hydrogen Substances 0.000 claims abstract description 44
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 210000004185 liver Anatomy 0.000 claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- 229910052751 metal Inorganic materials 0.000 claims abstract description 23
- 239000002184 metal Substances 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 18
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 241000234282 Allium Species 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 14
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 12
- 238000003809 water extraction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 229910012375 magnesium hydride Inorganic materials 0.000 claims description 6
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 5
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims description 5
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 5
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 5
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 48
- 230000035622 drinking Effects 0.000 abstract description 15
- 208000019423 liver disease Diseases 0.000 abstract description 12
- 231100000283 hepatitis Toxicity 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 7
- 206010019233 Headaches Diseases 0.000 abstract description 6
- 231100000869 headache Toxicity 0.000 abstract description 6
- 208000006454 hepatitis Diseases 0.000 abstract description 6
- 206010047700 Vomiting Diseases 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000008673 vomiting Effects 0.000 abstract description 4
- 235000005206 Hibiscus Nutrition 0.000 abstract description 2
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 abstract description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 abstract description 2
- 244000291564 Allium cepa Species 0.000 abstract 1
- 244000189799 Asimina triloba Species 0.000 abstract 1
- 235000006264 Asimina triloba Nutrition 0.000 abstract 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 22
- 239000008187 granular material Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 14
- 238000010171 animal model Methods 0.000 description 13
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 10
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108010024636 Glutathione Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 6
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000008789 Direct Bilirubin Methods 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000006000 Garlic extract Substances 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 208000036141 Viral hepatitis carrier Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- -1 hepatocyte promoters Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 229940096421 milk thistle extract Drugs 0.000 description 2
- 235000020727 milk thistle extract Nutrition 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 235000019997 soju Nutrition 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000018714 Allium canadense Nutrition 0.000 description 1
- 244000003363 Allium ursinum Species 0.000 description 1
- 235000005336 Allium ursinum Nutrition 0.000 description 1
- 235000005534 Allium vineale ssp. compactum Nutrition 0.000 description 1
- 235000003686 Allium vineale ssp. vineale Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 229910019440 Mg(OH) Inorganic materials 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- BKRIRZXWWALTPU-UHFFFAOYSA-N methyl 4-(4-methoxycarbonylphenyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CC=C(C(=O)OC)C=C1 BKRIRZXWWALTPU-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000009366 sericulture Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 숙취해소에 뛰어나며 알코올에 의한 간 손상을 예방 또는 치료용 조성물에 관한 것으로서, 더욱 상세하게는 기체 수소 내지 수소 용해 액상이 아닌 금속에 수소를 흡장시켜 체내에서 수소를 발생시킬 수 있는 수소 흡장 금속과 비타민C를 함유하는 숙취해소에 뛰어나며 알코올에 의한 간 손상을 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating liver damage due to alcohol, which is excellent in relieving hangovers, and more particularly, hydrogen storage capable of generating hydrogen in the body by storing hydrogen in a metal other than gaseous hydrogen or hydrogen dissolved liquid. It is excellent in relieving hangovers containing metal and vitamin C, and relates to a composition for preventing or treating liver damage caused by alcohol.
간은 당질, 단백질, 지방을 대사하는 중심기관이며, 체내에 들어온 물질을 산화, 환원, 가수분해 및 포합 반응을 통해 체내로 배설하는 기능을 담당하는 중요한 기관이다. 그러나 간질환이 초기단계에서 통증이나 자각증상이 잘 나타나지 않고 상당히 악화가 된 후에 발견되어 간은 ‘침묵의 장기’로 알려져 있다.The liver is a central organ that metabolizes sugars, proteins, and fats, and is an important organ responsible for excreting substances that have entered the body through oxidation, reduction, hydrolysis and conjugation reactions. However, the liver is known as a “silent organ” since liver disease is found after a significant deterioration without pain or subjective symptoms in the early stages.
간질환이 악화가 되면 변비, 과민성 대장 증후군 또는 변의 색 변이 등이 나타날 수 있으며, 간 손상이 있는 환자는 지속적인 구토가 있을 수 있고, 급격한 체중 저하를 초래하는 등의 변화가 일어날 수 있다. When liver disease worsens, constipation, irritable bowel syndrome, or color shift in stool may appear, and changes such as persistent vomiting may occur in patients with liver damage, and sudden weight loss may occur.
또한, 간 기능 장애로 인해 신체의 단백질 생성 및 순환 능력이 저해된 체액이 중력에 의해 하체로 내려가 다리, 발목 및 발의 부종과 같은 순환기 문제를 유발할 수 있으며, 피로감과 만성피로, 기억력 감퇴 등의 간 손상의 가장 흔한 증상이 발생할 수 있다.In addition, due to liver dysfunction, body fluids that have inhibited the body's ability to produce proteins and circulate may descend to the lower body by gravity and cause circulatory problems such as swelling of the legs, ankles and feet, and liver failure, such as fatigue, chronic fatigue, and memory loss. The most common symptoms of injury can occur.
심각한 간 손상 시에 나타나는 징후로는 혈액과 체내의 알부민과 단백질의 수치가 높게 유지됨에 따라 복부에서 유체(복수) 축적을 일으켜 복부가 부어오르는 현상이 있으며, 피부와 눈이 노랗게 되는 황달도 간 손상의 징후이다. Signs of severe liver damage include swelling of the abdomen due to accumulation of fluid (ascites) in the abdomen as the levels of albumin and protein in the blood and body remain high, and jaundice in which the skin and eyes become yellow is also liver damage. Is a sign of.
또한, 오른쪽 위 복부 혹은 흉곽 우측 하단 부분의 통증(간의 통증)이 있을 수 있고, 혈류에서 증가된 빌리루빈 수치로 인해 소변이 짙은 노란색으로 변할 수 있으며, 피부의 간지러움이나 박리(벗겨짐)가 발생하기도 한다.In addition, there may be pain in the upper right abdomen or in the lower right part of the ribcage (liver pain), urine may turn dark yellow due to increased bilirubin levels in the bloodstream, and itching or peeling (peeling) of the skin may occur. .
간 손상의 원인에는 간염 바이러스(A, B, C 등), 알코올(음주), 그리고 비알코올성 지방간 등이 대부분으로, 통계에 따르면 최근 국내 알코올성 간질환으로 발생하는 치료비용은 매년 급증하는 추세다. 또한, 국내 한 생명보험사의 통계를 분석해 봐도 사망 원인 중 알코올성 간질환 사망자가 10년 전과 비교해 7배로 급증했다. 지속적인 알코올 섭취로 인해 유발되는 알코올성 간질환은 국내를 비롯한 전 세계적인 사회적인 문제로 대두하고 있는데, 특히 알코올성 지방간 및 간염이 지속되면 간 섬유화 및 간경변으로 회복을 기대할 수 없는 단계에 이르게 되어 간 이식만이 유일한 치료방법으로 남게 된다.Most of the causes of liver damage are hepatitis virus (A, B, C, etc.), alcohol (drinking), and non-alcoholic fatty liver, and according to statistics, the cost of treatment caused by alcoholic liver disease in Korea is increasing every year. In addition, even when analyzing the statistics of a domestic life insurance company, among the causes of death, the number of deaths from alcoholic liver disease has increased by 7 times compared to 10 years ago. Alcoholic liver disease caused by continuous alcohol intake is emerging as a social problem around the world, including in Korea. In particular, if alcoholic fatty liver and hepatitis persist, recovery from liver fibrosis and cirrhosis can not be expected, so liver transplantation is the only one. It remains a treatment method.
한편, 국립암센터 통계자료에 의하면 우리나라 간염 바이러스 보균자의 60~70%가 B형 간염보균자이며, 특히 간암 환자의 75%가 B형 간염보균자이고, 전체인구의 5~10%가 만성 B형 간염 바이러스 보균자라는 통계도 있으며, B형 C형 간염 바이러스 및 다양한 간의 만성질환은 세계적으로 가장 빈도가 높은 악성종양인 간암의 원인이 되기도 한다.Meanwhile, according to statistics from the National Cancer Center, 60-70% of Korean hepatitis virus carriers are hepatitis B carriers, and 75% of liver cancer patients are hepatitis B carriers, and 5-10% of the total population is chronic hepatitis B. There are statistics that it is a virus carrier, and hepatitis B C virus and various chronic diseases of the liver are the causes of liver cancer, the most frequent malignant tumor in the world.
종래 간질환 치료제로는 현재 간 기능 보조제, 항바이러스제, 간세포 촉진제, 면역억제제, 섬유화억제제, 비페닐디메틸디카르복실레이트, 인터페론 등이 사용되고 있으나, 낮은 치료 효과와 높은 부작용 및 이를 보완하기 위한 이들 약의 병용투여는 치료효과만 증대되는 것이 아니라 부작용도 나타나고 있는 것으로 알려져 있어, 부작용이 적은 간 기능 개선용 기능성 원료 개발연구가 필요하다.Conventional liver disease treatments currently include liver function adjuvants, antiviral agents, hepatocyte promoters, immunosuppressants, fibrosis inhibitors, biphenyldimethyldicarboxylate, interferon, etc., but these drugs have low therapeutic effect, high side effects, and supplements. It is known that the combined administration not only increases the therapeutic effect, but also shows side effects. Therefore, research on the development of functional ingredients for improving liver function with less side effects is needed.
우리나라 20세 이상 성인 남자의 음주율은 83.3%로 매우 높고 여성의 음주율 또한, 54.9%로 급격히 증가하는 추세이며, 잘못된 음주 문화로 인하여 과음에 심각하게 노출되어 있다. 알코올의 과다 섭취로 인한 피해는 간질환을 비롯하여 각종 질환의 병인이 됨은 물론 개인, 가정, 사회의 정서와 생활에 부정적인 영향을 미침으로써 국가적으로 막대한 경제, 사회적 손실을 야기하고 있다.The drinking rate of adult men over 20 years old in Korea is very high at 83.3%, and the drinking rate of women is also rapidly increasing to 54.9%, and they are seriously exposed to excessive drinking due to the wrong drinking culture. The damage caused by excessive consumption of alcohol not only causes liver disease and other diseases, but also negatively affects the emotions and lives of individuals, families, and society, causing enormous economic and social losses in the country.
지나친 과음은 여러 형태의 부작용을 가져오는데, 예로 갈증, 전신권태, 피로감, 기억상실, 복부팽만감, 소화불량, 구토, 설사, 비타민 결핍현상으로 고생하는 경우가 많고, 알코올 중독에 걸릴 위험성도 그만큼 증가된다.Excessive drinking causes many types of side effects, such as thirst, general malaise, fatigue, memory loss, bloating, indigestion, vomiting, diarrhea, and vitamin deficiency, and increases the risk of alcoholism. do.
간 질환 중에서 만성적인 음주에 의해 발생하는 질환은 알코올성 지방간, 알코올성 간염, 알코올성 간경변으로 크게 나누어지지만 한 사람에게서 순수한 한 가지 병만 나타나는 경우는 드물고, 각 병이 개인마다 다양한 정도로 나타나게 된다.Among liver diseases, diseases caused by chronic drinking are largely divided into alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis, but only one disease is rarely seen in one person, and each disease appears to varying degrees for each individual.
미국에서는 가장 흔한 간경변의 원인이며 우리나라에서는 바이러스성 간염 다음으로 흔한 간경변의 원인이기도 하다.It is the most common cause of cirrhosis in the United States and is the second most common cause of cirrhosis after viral hepatitis in Korea.
정상적인 알코올 대사과정은 알코올이 섭취되는 경우, 위장, 또는 소장에서 흡수되어 그 중 10%는 호흡, 땀, 소변 등으로 배설되고, 나머지 90%의 알코올은 혈관 중에 들어가 간에서 대사된다(M Nakanishi; Saishin Igaku, 31, p2086, 1976) 이어서 간세포에 존재하는 알코올 탈수소효소(alcohol dehydrogenase, ADH)가 알코올을 아세트알데하이드로 산화시키고, 아세트알데하이드는 간세포에서 아세트알데하이드 탈수소효소(acetaldehydedehydrogenase)에 의하여 아세트산으로 분해되어 전신의 근육이나 지방 조직으로 옮겨서 최종적으로는 탄산가스와 물로 분해된다. When alcohol is ingested, normal alcohol metabolism is absorbed in the stomach or small intestine, and 10% of it is excreted through breathing, sweat, and urine, and the remaining 90% of alcohol enters blood vessels and is metabolized in the liver (M Nakanishi; Saishin Igaku, 31, p2086, 1976) Subsequently, alcohol dehydrogenase (ADH) present in hepatocytes oxidizes alcohol to acetaldehyde, and acetaldehyde is decomposed into acetic acid by acetaldehyde dehydrogenase in hepatocytes. It is transferred to the entire body's muscle or fat tissue and finally decomposed into carbon dioxide and water.
그러나 과음으로 인해 이러한 분해 대사과정이 순조롭지 못하면 아세트알데하이드가 축적되어 뇌혈관 수축 현상이 발생하여 머리가 무겁고 두통이나 속쓰림 등의 숙취현상(hangover)이 발생하게 된다.However, if this decomposition metabolic process is not smooth due to excessive drinking, acetaldehyde accumulates and cerebrovascular contraction occurs, resulting in a heavy head and hangover such as headache and heartburn.
이와 같은 문제를 해결하는데 도움되는 간 건강에 도움을 주는 개별인정형 기능성 원료로는 밀크씨슬 추출물, 브로콜리스프라우트 분말, 표고버섯 균사체 추출물, 복분자 추출분말, 도라지 추출물 등이 있고 알코올성 손상으로부터 간 보호에 도움을 주는 기능성 원료는 헛개나무 추출물과 유산균 발효 다시마 추출물 등이 있다(식품의약품안전처, 2018).Individually recognized functional ingredients that help liver health that help solve such problems include milk thistle extract, broccoliprout powder, shiitake mushroom mycelium extract, bokbunja extract powder, bellflower extract, etc., and protect the liver from alcohol damage. Functional ingredients that are helpful for health include extracts from dulcis dulcis and fermented kelp extracts (Ministry of Food and Drug Safety, 2018).
간 보호용 조성물에 대한 종래기술로는 대한민국 등록특허 제10-0477957호([구기자로부터 분리된 간 보호 활성을 갖는 신규 피롤 유도체 및 이를 함유한 조성물), 대한민국 등록특허 제10-0633851호(가열건조처리 된 산마늘 추출물을 유효성분으로 함유하는 간 보호 또는 간질환의 예방 및 치료용 조성물), 대한민국 등록특허 제10-1106499호(헛개나무 어린 가지 추출물을 포함하는 간 보호 효과용 식품 조성물), 굼벵이의 간 독성회복효과(전정수 외, 한국잠사학회지; 50(2), p93, 2012), 장수풍뎅이의 간 보호 및 간세포 재생 효과(이은지 외, 생명과학회지; 25(3), p307, 2015), 귀뚜라미의 간 보호효과(안미영 외, 한국식품과학회지; 34(4), p684, 2002) 등이 있다.As a prior art for a composition for liver protection, Korean Patent Registration No. 10-0477957 ([New pyrrole derivative having liver protection activity isolated from Gugija and a composition containing the same), Korean Patent No. 10-0633851 (heat drying treatment) Liver protection or liver disease prevention and treatment composition containing the wild garlic extract as an active ingredient), Republic of Korea Patent No. 10-1106499 (food composition for liver protection effect including extract of sprig Liver toxicity recovery effect (Jeong-su et al., Journal of Korean Society of Sericulture; 50(2), p93, 2012), Liver protection and hepatocyte regeneration effect of beetle (Eunji Lee et al., Journal of Life Science; 25(3), p307, 2015), cricket Of the liver (Miyoung Ahn et al., Journal of Food Science and Technology; 34(4), p684, 2002).
숙취해소에 대해서는 대한민국 공개특허 제2002-0081995호(배합식품에 의한 숙취해소 및 간 기능 개선제와 그 제조방법), 대한민국 공개특허 제2002-0064151호(헛개나무로부터 분리된 간 독성 및 숙취해소 활성을 갖는 저급알코올 불용성 추출 분획 및 다당체 물질 및 이를 함유하는 조성물) 등의 특허에 쌀눈 엑스(구루메), 오리나무, 참나무 목초액, 갈화, 밀크씨슬 추출물 등의 여러 가지 식물에서 기원한 제제들이 숙취에 효능이 있다고 보고되어 있긴 하지만, 이들은 음주에 의해 유발되는 다양한 변화들 중에서 일부 항목에만 효과가 있거나 미미하다.Regarding hangover relieving, Korean Patent Application Publication No. 2002-0081995 (Hangover Relief and Liver Function Improvement Agent Using Blended Foods and Its Manufacturing Method), Korean Patent Application Publication No. 2002-0064151 (Hepatotoxicity and hangover relieving activity isolated from Hangover trees) In patents such as lower alcohol-insoluble extract fractions and polysaccharide substances and compositions containing the same), preparations derived from various plants such as rice snow extract (gurume), alder tree, oak herb juice, brown flower, and milk thistle extract are effective for hangovers. Although reported to have been reported, they are only ineffective or insignificant in some of the various changes caused by drinking.
따라서 본 발명이 해결하고자 하는 과제는 숙취해소에 뛰어나며 알코올에 의한 간 손상을 예방 또는 치료용 조성물을 제공하는 것이다.Therefore, the problem to be solved by the present invention is to provide a composition for preventing or treating liver damage caused by alcohol and is excellent in relieving hangovers.
상기 과제를 해결하기 위하여, 본 발명은In order to solve the above problems, the present invention
파 새싹 열수 추출 동결 건조 분말; Green onion sprout hot water extract freeze-dried powder;
금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말: 및Freeze-dried powder extracted with hot water extracted with the same weight ratio of Geumhwagyu and Popo tree leaves: and
수소 흡장 금속을 활성성분으로 포함하는 것으로 특징으로 하는 간 보호, 숙취해소 또는 알코올성 간 질환의 예방 또는 개선용 건강기능식품 조성물.A health functional food composition for preventing or improving liver protection, hangover relief, or alcoholic liver disease, characterized in that it contains a hydrogen occluding metal as an active ingredient.
본 발명에 따른 건강기능식품 조성물에 있어서, 상기 수소 흡장 금속은 수소화마그네슘인 것이 바람직하다..In the health functional food composition according to the present invention, the hydrogen occluding metal is preferably magnesium hydride.
본 발명에 따른 건강기능식품 조성물은 중량비율로 상기 수소 흡장 금속 100일 때, 파 새싹 열수 추출 동결 건조 분말 150 내지 200, 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말 150 내지 200인 것을 특징으로 한다.Health functional food composition according to the present invention when the hydrogen occlusion metal 100 in weight ratio, 150 to 200 green onion sprout hot water extraction freeze-dried powder 150 to 200 hot water extraction freeze-dried powder mixture with the same weight ratio of Geumhwagyu and Popo tree leaves It features.
본 발명에 따른 건강기능식품 조성물은 비타민 C을 더 포함하며, 중량비율로 상기 수소 흡장 금속 100일 때, 파 새싹 열수 추출 동결 건조 분말 150 내지 200, 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말 150 내지 200, 비타민 C 10 내지 20인 것을 특징으로 한다.The health functional food composition according to the present invention further comprises vitamin C, and when the hydrogen occlusion metal is 100 in a weight ratio, hot water extraction of green onion sprouts, freeze-dried powder 150 to 200, hot water extraction of a mixture in the same weight ratio of Geumhwagyu and P. It is characterized in that the freeze-dried powder 150 to 200, vitamin C 10 to 20.
본 발명에 따른 건강기능식품 조성물에 있어서, 상기 알코올성 간 질환은 알코올성 간염, 알코올성 지방간 또는 알코올성 간경화를 의미한다.In the health functional food composition according to the present invention, the alcoholic liver disease means alcoholic hepatitis, alcoholic fatty liver or alcoholic cirrhosis.
상술한 바와 같은 본 발명의 조성물은 간 손상 억제 효과가 있고, 간염 지수를 낮추어 각종 간질환을 예방 또는 치료할 수 있는 조성물로 이용이 가능하며, 알코올 분해 효과 및 아세트알데하이드 분해 효과가 매우 우수하고 음주 후 다음날의 두통, 구토증상 등을 완화하여 음주 전/후에 복용하는 간 보호 또는 숙취해소용 조성물로도 매우 유용하다. The composition of the present invention as described above has the effect of inhibiting liver damage, can be used as a composition that can prevent or treat various liver diseases by lowering the hepatitis index, and has excellent alcohol decomposition effect and acetaldehyde decomposition effect, and after drinking It is also very useful as a composition for protecting the liver or relieving hangovers taken before/after drinking by relieving headaches and vomiting symptoms the next day.
이하 본 발명을 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명은 활성성분으로 수소 흡장 금속; 비타민 C; 및 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말을 활성성분으로 포함하는 것을 특징으로 하는 간 보호 또는 숙취해소용 조성물을 제공한다.The present invention is a hydrogen storage metal as an active ingredient; Vitamin C; And it provides a composition for liver protection or hangover, characterized in that it comprises a mixture of hot water extracted freeze-dried powder in the same weight ratio of Geumhwagyu and Popo tree leaves as an active ingredient.
본 발명은 수소, 비타민C 및 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말와의 복합작용에 간 보호 또는 숙취해소, 더욱 나아가서는 알코올성 간염, 알코올성 지방간 또는 알코올성 간경화로 대표되는 알코올성 간질환의 예방 또는 치료에 효과가 확인이 되어 완성된 것이며, 특히 수소를 체내에 흡수시키는 방법으로 본 발명은 가스 형태로 수소를 흡입하거나 수소를 용해한 수소수를 마시는 방법을 체내에 수소를 전달하던 종래의 방법이 아닌 고체 형태로 수소를 섭취하여 섭취된 고체가 위 내지 장 등의 체내 기관에서 수소를 발생시켜 수소가 체내 흡수시키도록 한 것이다.The present invention protects the liver or relieves hangovers in a combination with hydrogen, vitamin C, and the same weight ratio mixture of Geumhwagyu and Popo tree leaves and freeze-dried powder extracted with hot water, furthermore, alcoholic liver disease represented by alcoholic hepatitis, alcoholic fatty liver or alcoholic cirrhosis It was completed by confirming the effect of preventing or treating hydrogen. In particular, as a method of absorbing hydrogen into the body, the present invention uses a method of inhaling hydrogen in gaseous form or drinking hydrogen water dissolved in hydrogen. The intake of hydrogen in a solid form, rather than a method, generates hydrogen in the body organs such as the stomach and intestines, allowing the hydrogen to be absorbed in the body.
이와 같은 방법에 의하는 경우 종래의 방법보다 고 농도로 수소를 체내 수소 흡수에 달성시키고 공급되는 수소의 농도를 일정하게 유지할 수 있어 수소에 의한 체내 효과도 배가시킬 수 있으며 생산 및 보관의 편의성이 증대되어 섭취하는 환자의 순응성이 높으며, 수소를 생성할 수 있는 원가가 절감이 되는 장점이 있으며, 특히 산제, 정제, 과립제, 캡슐제, 환제 등 분말 타입의 복합제제를 만들기 용이한 장점이 있다.In the case of such a method, it is possible to achieve hydrogen absorption in the body at a higher concentration than the conventional method and to maintain a constant concentration of supplied hydrogen, thereby doubling the internal effect of hydrogen and increasing the convenience of production and storage. It has the advantage of high compliance of the ingested patient, reducing the cost of generating hydrogen, and in particular, it has the advantage of easy to make powder-type complex formulations such as powders, tablets, granules, capsules, and pills.
본 발명에서 사용되는 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말은 다음과 같이 제조된다.The hot water extraction freeze-dried powder of a mixture of the same weight ratio of Geumhwagyu and Popo tree leaves used in the present invention is prepared as follows.
뿌리를 포함하는 금화규 전체와 포포나무 잎을 동일 중량비율로 혼합한 다음에 이를 열수 추출한 후에 열수 추출물을 동결건조하여 수분을 함유하지 않은 분말로 제조한 것이며, 열수 추출 방법 및 동결건조는 본 발명이 속하는 기술분야에 널리 알려진 것이라면 특별한 제한 없이 사용이 가능하다.After mixing the whole Geumhwagyu including the roots and the leaves of Popo tree at the same weight ratio, the hot-water extract was freeze-dried to prepare a powder containing no moisture after hot-water extraction, and the hot-water extraction method and freeze-drying are the present invention. As long as it is widely known in the technical field to which it belongs, it can be used without particular limitation.
본 발명에서 상기 금화규는 히비스커스(Hibiscus)속에 속하는 일년생 초본식물인 금화규는 일명 야생부용이라고도 불리우며 본초강목에 실려 있는 약용식물로서, 중국에서 복원이 되어 재배되기 시작하였으며, 최근에는 중국으로부터 국내로 종자가 유입되어 국내에서도 재배가 이루어지고 있다. 금화규는 7~8월이면 사람의 키를 넘게 자라는데 꽃송이 직경이 보통 16~18cm되고 꽃잎은 노랗고 엷으며 주홍빛이 나는 꽃술에 잎은 짙푸른 색의 풍엽형으로 매우 아름답다. 금화규는 개화시간이 대 여섯 시간밖에 안되기 때문에 제때에 수확하는 것이 아주 중요하다고 한다. 금화규의 꽃은 7월말부터 따서 잘게 찢어서 말려 분말로 하여 식품. 화장품 및 차의 원료가 사용되며, 금화규의 잎 역시 다양한 생리활성 물질을 함유하고 있어 여러 용도에 이용되고 있다.In the present invention, the Geumhwagyu is an annual herbaceous plant belonging to the genus Hibiscus. The Geumhwagyu is also called a wild bouillon and is a medicinal plant carried on the primrose, and has been restored and cultivated in China. Seeds have been introduced and cultivation is taking place in Korea. Geumhwagyu grows beyond the height of a person in July-August. The flower blossoms are usually 16-18cm in diameter, the petals are yellow, thin, and scarlet. The leaves are dark blue, and the leaves are very beautiful. Geumhwagyu is said to be harvested in a timely manner because the flowering time is only about six hours. Geumhwagyu flowers are picked from the end of July, shredded, dried, and powdered. Raw materials for cosmetics and tea are used, and the leaves of Geumhwagyu also contain various physiologically active substances and are used for various purposes.
본 발명에서 사용되는 포포나무는 북미가 원산지인 낙엽 활엽수로서 개화시기는 4월경이며 열매는 9~10월경에 수확하는데, 이 열매는 바나나, 파인애플, 망고를 합친 듯한 상쾌한 맛이 나며 당도가 좋고 단백질 함유량이 높으며, 최근 강력한 항암성분을 지닌 것으로 알려지면서 의학계 및 건강식품으로써 주목받고 있다.The popo tree used in the present invention is a deciduous broad-leaved tree native to North America. The flowering time is around April and the fruit is harvested around September to October. This fruit has a refreshing taste like a combination of banana, pineapple, and mango, and has good sugar content and protein. It has a high content and is recently known to have a strong anti-cancer component, and is attracting attention as a medical and health food.
또한, 본 발명에서 사용되는 비타민C는 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한이 없이 사용 가능하며, 수소 흡장 금속은 다음과 같다.In addition, vitamin C used in the present invention can be used without particular limitation as long as it is widely known in the technical field to which the present invention belongs, and the hydrogen occluding metal is as follows.
금속은 일반적으로 그 표면 혹은 내부에 수소를 보유하고 있다. 그 중에서도, 팔라듐이나 마그네슘은 금속 내에 수소를 다량으로 보유할 수 있고, 니켈이나 백금은 표면에 수소를 보유할 수 있는데, 본 발명이 이와 같은 수소 흡장 금속을 이용하여 조성물을 제공하는 것이다.Metals generally have hydrogen on their surface or inside. Among them, palladium and magnesium can hold a large amount of hydrogen in the metal, and nickel or platinum can hold hydrogen on the surface, and the present invention provides a composition using such a hydrogen storage metal.
수소가 유리된 후 남은 금속 중에서 팔라듐, 니켈, 백금은 물에 불용의 금속이 체내에 잔존하게 되므로 안전성의 관점으로부터 바람직하지 않을 수 있어 수소화마그네슘(일반적으로 MgH2의 화학식으로 나타냄)은 하기 반응식과 같이 물과 반응하여 분자 상 수소를 발생시킬 수 있으며, 체내 안전성이 확인된 마그네슘이 남기 때문에 경구 투여를 위한 수소가 흡장된 금속으로 가장 바람직하다.Among the remaining metals after hydrogen is liberated, palladium, nickel, and platinum may be undesirable from the viewpoint of safety because metals insoluble in water remain in the body. Therefore, magnesium hydride (generally represented by the formula of MgH 2 ) can be obtained from the following reaction formula. Likewise, it can react with water to generate molecular hydrogen, and since magnesium, which has been confirmed to be safe in the body, remains, it is most preferable as a metal containing hydrogen for oral administration.
<반응식><Reaction Scheme>
MgH2+2H2O → Mg(OH)2+2H2 MgH 2 +2H 2 O → Mg(OH) 2 +2H 2
이와 같은 본 발명의 조성물의 제조 기술은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한 없이 이용하며 당업자라면 충분히 제조 가능하다.As long as the technology for preparing the composition of the present invention is widely known in the technical field to which the present invention pertains, it is used without particular limitation and can be sufficiently manufactured by those skilled in the art.
또한, 1회 복용으로 수소가 발생하는 시간을 연장하기 위하여 과립제를 제조할 때 위용성 과립과 장용성 과립으로 따라 제조하여 이를 혼합하여 1회 복용의 과립제로하여 섭취할 수 있으며, 이와 같은 과립제를 충전하거나 타정하여 캡슐제나 정제를 만들 수 있다.In addition, in order to prolong the generation time of hydrogen in a single dose, when preparing granules, gastric granules and enteric granules can be prepared and mixed and consumed as a single dose granule. Or, you can make capsules or tablets by tableting.
이와 같은 조성물을 섭취하게 되면 1차적으로 위에서 위용성 과립이 작용하여 수소가 발생하고, 이어서 섭취 물이 장으로 가면 장용성 과립이 작용하여 수소가 발생하게 되어 수소 발생의 시간을 연장시키는 것이 가능하게 된다. When ingesting such a composition, gastric granules act primarily in the stomach to generate hydrogen, and when the ingested water goes to the intestine, enteric granules act to generate hydrogen, making it possible to prolong the time for hydrogen generation. .
상술한 바와 같은 본 발명에 의한 간 보호 효과는 g-GT(gamma-glutamyl phosphatase), GPT(glutamate-pyruvate trabsminase), GOT(glutamate-oxaloacetlate transminase), AP(alkaline phosphatase) 및 TBIL(total bilirubin), DBIL(direct bilirubin)로 이루어진 군 중에서 선택되는 1종 이상의 간 손상 지표 인자를 저하시키는 것을 특징으로 할 수 있으며, 숙취해소효과는 혈중 알코올 농도, 아세트알데하이드 농도, 호흡 알코올 농도 및 혈중 알코올 농도에서 선택된 1종 이상의 숙취해소 지표 인자를 저하시키거나 알데하이드 탈수소효소의 활성을 증가시키는 것을 특징으로 할 수 있다.The liver protective effect according to the present invention as described above is g-GT (gamma-glutamyl phosphatase), GPT (glutamate-pyruvate trabsminase), GOT (glutamate-oxaloacetlate transminase), AP (alkaline phosphatase) and TBIL (total bilirubin), It may be characterized by lowering at least one indicator of liver damage selected from the group consisting of direct bilirubin (DBIL), and the hangover relief effect is 1 selected from blood alcohol concentration, acetaldehyde concentration, respiratory alcohol concentration, and blood alcohol concentration. It may be characterized by lowering a hangover relieving index factor or increasing the activity of aldehyde dehydrogenase.
본 발명의 조성물의 투여량은 치료받을 대상의 연령, 성별, 체중과 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여 경로 및 처방 자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.01mg/kg/일 내지 대략 2,000mg/kg/일의 범위이다.The dosage of the composition of the present invention will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration, and the judgment of the prescriber. Dosage determination based on these factors is within the level of one of skill in the art, and dosages generally range from 0.01 mg/kg/day to approximately 2,000 mg/kg/day.
더 바람직한 투여량은 1mg/kg/ 일 내지 500mg/kg/일이다. 투여는 하루에 한 번 투여할 수 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.A more preferred dosage is between 1 mg/kg/day and 500 mg/kg/day. Administration may be administered once a day, or may be divided several times. The above dosage does not in any way limit the scope of the present invention.
또한, 본 발명의 조성물을 구성하는 활성성분들의 혼합 중량 비율은 특별한 제한이 없으나, 다양한 실험 결과 조성물 전체에 대하여 상기 수소 흡장 금속 50 내지 80중량%, 비타민 C 10 내지 25중량%, 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말 10 내지 25중량%인 것이 바람직하다.In addition, the mixing weight ratio of the active ingredients constituting the composition of the present invention is not particularly limited, but as a result of various experiments, 50 to 80% by weight of the hydrogen occluding metal, 10 to 25% by weight of vitamin C, gold hwagyu and foam It is preferable that it is 10 to 25% by weight of freeze-dried powder extracted with hot water in the same weight ratio of tree leaves.
본 발명은 다른 실시예로서 파 새싹 열수 추출물을 동결 건조한 분말을 더 포함할 수 있으며, 이 경우는 조성물 전체에 대하여 상기 수소 흡장 금속 50 내지 80중량%, 비타민 C 5 내지 20중량%, 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말 2 내지 20중량%, 파 새싹 열수 추출 동결 건조 분말 5 내지 20중량%인 것이 바람직하다.The present invention may further include a freeze-dried powder of the green onion sprout hot water extract as another embodiment, in this case, 50 to 80% by weight of the hydrogen occluding metal, 5 to 20% by weight of vitamin C, and Geumhwagyu and It is preferable that the mixture is 2 to 20% by weight of hot water extracted freeze-dried powder and 5 to 20% by weight of hot water extracted freeze-dried green onion sprouts.
상기 파 새싹은 파 씨를 파종한 후에 3 내지 10일 정도 자란 어린 새싹을 의미하며, 열수 추출 및 동결 건조 방법은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한 없이 사용 가능하다.The green onion sprout refers to a young sprout grown for about 3 to 10 days after sowing the green onion seeds, and hot water extraction and freeze drying methods can be used without particular limitation as long as they are widely known in the technical field to which the present invention belongs.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 여기서 설명되는 실시예에 의해 본 발명은 한정되지 않으며 다른 형태로도 충분히 구체화될 수 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지도록, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다.Hereinafter, a preferred embodiment of the present invention will be described in detail. The present invention is not limited by the examples described herein and may be sufficiently embodied in other forms. Rather, it is provided to sufficiently convey the spirit of the present invention to those skilled in the art so that the contents introduced herein are thorough and complete.
<< 실시예Example : 본 발명에 따른 조성물 제조>: Preparation of the composition according to the present invention>
수소 흡장 금속으로서 수소화마그네슘, 비타민C, 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말, 파 새싹 열수 추출 동결 건조 분말은 표 1과 같은 중량 비율로 혼합한 본 발명에 따른 조성물을 제조하였다. The composition according to the present invention was prepared by mixing magnesium hydride as hydrogen occluding metal in the same weight ratio of magnesium hydride, vitamin C, Geumhwagyu, and phofo tree leaf in the same weight ratio, hot-water extraction freeze-dried powder, and green onion sprout hot-water extraction freeze-dried powder as shown in Table 1. I did.
상기 금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말은 금화규와 포포나무 잎 각각 1kg을 물 1ℓ에 넣고 약 20시간 달인 후에 이를 농축한 후에 동결건조하여 분말로 제조한 것이다.The freeze-dried powder extracted with hot water in the same weight ratio of Geumhwagyu and Popo tree leaves is prepared as a powder by adding 1kg of Geumhwagyu and Popo tree leaves to 1 liter of water, decoction for about 20 hours, and then freeze-drying them.
상기 파 새싹 열수 추출 동결 건조 분말은 파종한 지 1주일 된 파 새싹 1kg을 물 1ℓ에 넣고 약 20시간 달인 후에 이를 농축한 후에 동결건조하여 분말로 제조한 것이다.The green onion sprout hot-water extract freeze-dried powder is prepared as a powder by adding 1 kg of green onion sprouts 1 week after sowing into 1 liter of water, decoding for about 20 hours, concentrating and freeze-drying them.
<< 실험예Experimental example : 알코올 투여 동물 모델 유도 및 물질 투여>: Alcohol administration animal model induction and substance administration>
실험동물은 체중 160~180g 범위의 Sprague-Dawley의 수컷 흰쥐를 (주)대한바이오링크(음성, 한국)에서 구입하였다. 사육환경은 온도 20±2℃, 습도 55±1%(RH), 명암주기 12시간 간격으로 유지하여 1주일간 순환시켰다.The experimental animals were Sprague-Dawley male rats with a body weight ranging from 160 to 180 g were purchased from Daehan Biolink (Eumseong, Korea). The breeding environment was maintained at 20±2℃ temperature, 55±1% (RH) humidity, and 12 hour intervals of light and dark cycles and circulated for 1 week.
사료는 실험동물용 고형사료 (PMI Nutrition International)를 매일 일정한 시간에 일정량을 주었고, 물은 멸균 수를 물병을 이용하여 자유롭게 섭취하도록 하였다.The feed was given a certain amount of solid feed for experimental animals (PMI Nutrition International) at a certain time every day, and the water was freely ingested using sterile water using a water bottle.
대조군으로서, 실험동물용 고형사료(PMI Nutrition International)를 롤밀로 70mesh 입자크기로 분쇄한 다음 역시 역회전식 과립기로 30kg/cm의 경도를 가지는 과립으로 한 후 건조한 것을 투여하였으며, 시험군으로는 실험동물용 고형사료(PMI Nutrition International)에 실시예의 조성물을 5:5중량 비율로 혼합한 다음에 대조군과 동일하게 제조하였다. As a control, a solid feed for experimental animals (PMI Nutrition International) was pulverized with a roll mill to a particle size of 70 mesh, then made into granules having a hardness of 30 kg/cm with a counter rotating granulator, and then dried. As a test group, experimental animals For solid feed (PMI Nutrition International), the composition of the example was mixed in a ratio of 5:5 by weight, and then prepared in the same manner as the control group.
이렇게 제조한 일반사료 과립, 실시예 조성물 함유 과립을 실험동물(각 군 당 8마리)에게 무제한 급여하였다.The general feed granules prepared in this way and the granules containing the Example composition were fed unlimitedly to experimental animals (8 animals per each group).
이때, 에탄올 급여는 25(v/v)% 에탄올 수용액을 5mL/kg, bw/day의 수준으로 stomach tube를 통하여 6주간 매일 경구 투여하였다. 즉, 8주간의 사육기간 중 1주간은 새로운 혼합분말 사료에 적응기간을 두기 위하여 에탄올을 투여하지 않았으며, 이후 6주간 투여한 후 마지막 1주는 투여하지 않았다. At this time, ethanol feeding was administered orally for 6 weeks through a stomach tube at a level of 25(v/v)% ethanol aqueous solution at a level of 5mL/kg and bw/day. In other words, ethanol was not administered for 1 week of the 8-week breeding period to allow the adaptation period to the new mixed powder feed, and after 6 weeks of administration, the last 1 week was not administered.
시험 처리는 아래 표 2에 나타낸 바와 같고, 이후의 실험동물의 상태 평가 결과는 하기 표 2의 구분을 따라 표기하였다.The test treatment is as shown in Table 2 below, and the results of the subsequent evaluation of the condition of the experimental animals are indicated according to the divisions in Table 2 below.
<체중 변화 확인><Check weight change>
실험예의 모든 동물에 대하여 1일 1회 증상 관찰을 하였다. 체중은 일정한 시간에 5일 단위로 동물용 체중계를 이용하여 측정하여 그 결과를 표 3에 나타냈다.Symptoms were observed once a day for all animals of the experimental example. Body weight was measured using an animal weight scale every 5 days at a certain time, and the results are shown in Table 3.
이 시험기간 동안 폐사한 동물은 없었으며, 특이적인 임상증상을 나타낸 동물은 관찰되지 않았다. 상기 표 3을 보면, 체중은 시험기간 동안 모든 군에서 전체적으로 상승하였으나 실시예의 군은 대조군과 거의 유사한 상승폭을 보였으나 비교군의 경우에는 둔화 정도가 매우 심하였다. No animals died during this test period, and no animals with specific clinical symptoms were observed. As shown in Table 3, the body weight overall increased in all groups during the test period, but the group of the example showed almost the same increase as that of the control group, but the degree of slowing was very severe in the case of the comparison group.
<혈액 생화학적 분석결과><Blood biochemical analysis results>
시험이 종료된 후 복부동맥으로부터 채혈된 혈액을 상온에 30분 정치시킨 후 3,000rpm으로 4℃에서 15분간 원심분리하여 혈청을 분리한 다음 혈청효소를 혈청 자동분석기(Dri-chem 2000, Fujifilm, Tokyo, Japan)를 이용하여 분석하였다. 혈청효소의 종류는 glutamate-pyruvate(GPT), glutamate-oxaloacetlate(GOT), g-GT(gammaphosphatase), alkaline phosphatase(AP), total bilirubin(TBIL) 및 direct-bilirubin(DBIL)로 총 6가지를 측정하여 하기 표에 나타냈다.After the test was completed, the blood collected from the abdominal artery was allowed to stand at room temperature for 30 minutes, then centrifuged at 4℃ for 15 minutes at 3,000 rpm to separate the serum, and then use the serum enzyme in an automatic serum analyzer (Dri-chem 2000, Fujifilm, Tokyo). , Japan). The types of serum enzymes are glutamate-pyruvate (GPT), glutamate-oxaloacetlate (GOT), g-GT (gammaphosphatase), alkaline phosphatase (AP), total bilirubin (TBIL) and direct-bilirubin (DBIL). And shown in the table below.
간질환의 진단에 사용되는 효소로는 GOT, GPT, g-GT 및 ALP 검사가 많이 이용된다. 이들 효소 활성 치의 증가는 세포장애 정도와 비교적 상관성이 높을 뿐만 아니라 다른 혈중 효소에 비하여 민감하게 변동한다.As enzymes used to diagnose liver disease, GOT, GPT, g-GT and ALP tests are widely used. The increase in the activity of these enzymes has a relatively high correlation with the degree of cell disorder and fluctuates more sensitively than other blood enzymes.
상기 표 4를 보면, 실시예 투여군에서 비교군보다 현저하게 감소하는 것을 확인할 수 있었다. Looking at Table 4, it was confirmed that the example administration group significantly decreased compared to the comparative group.
또한, Alkaline phosphatase(AP) 활성은 하기의 표 5에 나타냈다.In addition, Alkaline phosphatase (AP) activity is shown in Table 5 below.
상기 표 5를 보면, AP의 경우 비교군에 비해 본 발명의 실시예 군에서 평균 31.2% 개선되어 우수한 효과를 보였다.Referring to Table 5, in the case of AP, compared to the comparative group, the average of 31.2% was improved in the example group of the present invention, showing excellent effects.
AP 수치는 간세포의 손상/회복 사이클이 올라갈수록 상승하는 수치로 GPT 억제를 뒷받침하는 지표로써, 알코올과 함께 실시예의 분말로 제조한 과립을 투여한 군에서 효과적인 억제능이 있는 것이 확인되었기에, 이 본 발명의 조성물이 GOT나 billirubin 수치를 억제하는 활성을 뒷받침하는 지표가 된다고 할 수 있다.The AP level is a value that increases as the damage/recovery cycle of hepatocytes increases, and is an index supporting GPT inhibition, and it was confirmed that the group administered the granules prepared in the Example powder together with alcohol has an effective inhibitory ability. It can be said that the composition of is an indicator supporting the activity of inhibiting GOT or billirubin levels.
이어서 Gamma-glutamyl phosphatase(g-GT)가 고도로 증가되어 있다면 만성 담즙울체일 것이고 담도성 간경변증이나 경화성 담관염을 추정 진단할 수 있는데 g-GT의 활성을 분석한 결과는 표 6에 나타냈다.Subsequently, if Gamma-glutamyl phosphatase (g-GT) is highly increased, it will be chronic cholestasis, and biliary cirrhosis or sclerosing cholangitis can be estimated and diagnosed.
상기 표 6을 보면, g-GT는 비교군에 비해 본 발명의 실시예를 투여한 군에서 평균 20.6% 개선되어 우수한 효과를 보였다.Referring to Table 6, g-GT was improved by an average of 20.6% in the group to which the Example of the present invention was administered compared to the comparative group, showing excellent effects.
마지막으로 Total bilirubin(TBIL)이 혈중에 증가하는 경우에는 간에서 담도로 배설되지 않는 폐쇄성 황달로 볼 수 있는데 TBIL 활성을 분석한 결과는 표 7에 나타냈다.Lastly, when total bilirubin (TBIL) is increased in blood, it can be seen as obstructive jaundice that is not excreted from the liver into the biliary tract. The results of TBIL activity analysis are shown in Table 7.
상기 표 7을 보면, TBIL은 비교군에 비해 본 발명의 실시예를 투여한 군에서 평균 39% 개선되어 우수한 효과를 보였다.Referring to Table 7 above, TBIL was improved by an average of 39% in the group administered the Example of the present invention compared to the comparative group, showing excellent effects.
이러한 결과 역시 본 발명의 조성물이 간 보호 활성이 있음을 확인할 수 있다.These results can also be confirmed that the composition of the present invention has liver protective activity.
<조직학적 분석결과><Histological analysis results>
실험동물의 간 조직의 우엽을 절취하여 간 조직 내의 산화환원 기능에 관여하는 환원형 글루타치온(GSH)과 산화형 글루타치온(GSSG)의 함량을 측정하였다.The right lobe of the liver tissue of the experimental animal was cut to measure the content of reduced glutathione (GSH) and oxidized glutathione (GSSG) involved in the redox function in the liver tissue.
절취한 간 조직을 절편으로 만들고 칭량한 후 4배량의 01M 포타슘 포스페이트 버퍼(potassium phosphate buffer, pH 74)를 가해 얼음 중에서 조직분쇄기로 마쇄하여 효소가 포함된 효소액을 얻었다. 이러한 효소액을 가지고 환원형 글루타치온 함량 분석을 Ellman (1959) 및 S'wiergosz-Kowaleska 등(2006)의 방법에 따라 실시하였는데, 총 글라타치온 함량을 먼저 분석한 후 이 값에서 산화형 글루타치온의 함량을 뺀 값을 환원형 글루타치온으로 하여 그 값을 표 8에 나타내었다.The cut liver tissue was sliced and weighed, and then 4 times the amount of 01M potassium phosphate buffer (pH 74) was added and ground with a tissue grinder in ice to obtain an enzyme solution containing enzymes. With this enzyme solution, the reduced glutathione content was analyzed according to the method of Ellman (1959) and S'wiergosz-Kowaleska et al. (2006). The subtracted value was used as reduced glutathione, and the values are shown in Table 8.
환원형 글루타치온은 글루타치온에 SH(S는 황, H는 수소)기가 붙어 있는 것을 말한다. 이러한 환원형 글루타치온은 유해한 활성 산소를 제거하는 역할을 하는데, 표 8을 보면, 환원형 글루타티온의 양은 비교군에 비해 실시예 투여군에서는 평균적으로 14.5% 증가시켜 실시예 조성물이 항산화작용에 더 도움을 주는 것임을 확인할 수 있었다.Reduced glutathione refers to glutathione with an SH (S for sulfur, H for hydrogen) group attached to it. This reduced glutathione plays a role in removing harmful active oxygen.See Table 8, the amount of reduced glutathione increased by 14.5% on average in the Example administration group compared to the comparative group, so that the Example composition more helpful in antioxidant activity. I could confirm that it was.
<염증 및 <Inflammation and 산화적Oxidative 스트레스 억제 효과 확인> Checking the stress suppression effect>
실험 모든 동물의 혈액에서 염증 cytokine인 TNF-α와 IL-1β를 측정하였으며 이에 대한 결과는 표 9에 나타냈다. In the blood of all experimental animals, the inflammatory cytokines TNF-α and IL-1β were measured, and the results are shown in Table 9.
각 실험은 R&D systems에서 제공하는 kit(TNF-α IRTA800)를 이용하여 확인하였다. 이 과정을 간단히 설명하자면, 혈액 중에 존재하는 각 cytokine과 결합할 수 있는 antibody가 precoating된 96 well plate에 본 실험에서 얻은 혈청을 실험에서 2시간 동안 반응시킨 후, 2차 항체를 응시키고, 그 후 결합된 양을 알 수 있는 substrate solution을 처리하여 540 ㎚ 또는 570 ㎚에서 흡광도를 확인하였다.Each experiment was confirmed using a kit (TNF-α IRTA800) provided by R&D systems. To briefly explain this process, the serum obtained in this experiment was reacted for 2 hours in the experiment in a 96 well plate precoated with an antibody capable of binding to each cytokine present in the blood, and then a secondary antibody was coagulated. The absorbance was confirmed at 540 nm or 570 nm by treating a substrate solution with an unknown amount of bound.
상기 표 9에 보면, 비교군 TNF-α와 IL-1β의 발현이 모두 증가하였으나, 실시예 투여군에서는 이들 사이토카인과 마커의 발현이 정상식이군인 대조군에 가깝게 현저히 감소되어 알코올 섭취로 인한 염증물질의 생성이 억제됨을 알 수 있었다.As shown in Table 9, both the expression of TNF-α and IL-1β in the comparative group increased, but in the Example administration group, the expression of these cytokines and markers was significantly reduced close to that of the control group, which was a normal diet group, and thus It was found that production was suppressed.
이상과 같은 결과를 통해 본 발명의 조성물이 간 보호 효능이 매우 우수함을 알 수 있으며, 이러한 기능을 통해 알코올로 인해 발생하는 간염이나 지방간 등 각종 알코올성 질환 예방, 개선 또는 치료용 약학 조성물이나 건강기능식품으로 상업적 이용이 가능하다.From the above results, it can be seen that the composition of the present invention has very excellent liver protection effect, and through this function, a pharmaceutical composition or health functional food for preventing, improving or treating various alcoholic diseases such as hepatitis or fatty liver caused by alcohol It is commercially available.
<혈중 알코올 감소 효능 평가><Evaluation of blood alcohol reduction efficacy>
실시 예에서 제조된 조성물의 알코올 분해효과를 확인하기 위하여 실험동물에 알코올을 투여한 다음 1, 3, 5시간 후의 혈중 알코올농도와 아세트알데하이드 농도를 측정하여 체내에서의 알코올 분해효과를 평가하였다. 실험동물 수는 군 당 6마리로 하였고 각 동물 실험군의 구분은 상기 표 2의 표기를 따랐다.In order to confirm the alcohol decomposition effect of the composition prepared in the examples, alcohol was administered to the experimental animals, and then the blood alcohol concentration and acetaldehyde concentration were measured after 1, 3, and 5 hours to evaluate the alcohol decomposition effect in the body. The number of experimental animals was 6 per group, and the classification of each animal experimental group followed the notation in Table 2 above.
알코올 투여는 에탄올 25(v/v)% 에탄올 수용액을 3g/kg, bw/day의 수준으로 stomach tube를 통하여 경구 투여하였으며, 각 시료는 실시예의 과립제조용 분말 500mg/kg을 알코올 투여량과 동량의 증류수에 분산시켜 알코올 투여 전, 후 30분에 2회 투여하였다. Alcohol was administered orally through a stomach tube of 25 (v/v)% ethanol aqueous solution at a level of 3 g/kg and bw/day, and each sample was prepared by using 500 mg/kg of the granule preparation powder of the example in the same amount as the alcohol dose. It was dispersed in distilled water and administered twice at 30 minutes before and after alcohol administration.
투여한 다음 1, 5시간 후의 혈중 알코올 농도와 아세트알데하이드 농도를 측정하여 체내에서의 알코올 분해효과를 평가하였다. 측정방법은 실험동물의 복대 정맥에서 채혈하고, 채혈한 혈액을 3000rpm에서 30분간 원심 분리하여 획득한 혈청에 알코올의 농도를 에탄올 측정키트(abcam AB6543)를 이용하여 측정하여 하기 표 10에 나타냈다.After administration, blood alcohol concentration and acetaldehyde concentration were measured 1 and 5 hours after administration to evaluate the alcohol decomposition effect in the body. As for the measurement method, blood was collected from the abdominal vein of an experimental animal, and the concentration of alcohol in the serum obtained by centrifuging the blood collected at 3000 rpm for 30 minutes was measured using an ethanol measurement kit (abcam AB6543), and is shown in Table 10 below.
상기 표 10을 보면, 비교군의 알코올 투여에 따른 혈중 알코올 농도 및 아세트알데하이드 농도는 시간이 지남에 따라 감소하였으나 그 감소 정도는 완만하였다. 반면, 알코올투여와 동시에 실시예 조성물을 투여한 군에서는 혈중 알코올 농도가 비교군에 비해 현저히 저하되었으며 또한, 아세트알데하이드 농도의 감소에서도 현저히 뛰어남을 확인할 수 있었다.Referring to Table 10, the blood alcohol concentration and acetaldehyde concentration according to the alcohol administration of the comparative group decreased with time, but the degree of reduction was gentle. On the other hand, it was confirmed that in the group to which the Example composition was administered at the same time as the alcohol administration, the blood alcohol concentration was significantly lowered compared to the comparative group, and was also remarkably excellent in the reduction of acetaldehyde concentration.
이처럼 본 발명의 조성물은 숙취해소 능력을 극대화해 혈중 에탄올과 아세트알데하이드 농도를 탁월하게 감소시키는 효과가 있음을 확인하였다.As such, it was confirmed that the composition of the present invention has an effect of remarkably reducing the concentration of ethanol and acetaldehyde in blood by maximizing the hangover relief ability.
<알데하이드 탈수소효소(<Aldehyde dehydrogenase ( ALDHALDH ) 활성 및 아세트알데하이드() Active and acetaldehyde ( ADHADH ) 생성량 조사>) Investigation of amount generated>
상기 실시예의 조성물이 알데하이드 탈수소효소(ALDH) 활성 및 아세트알데하이드(AD) 생성량에 미치는 영향을 조사하기 위하여 상기 실험예 1에서 획득한 실험동물의 혈청을 이용하여 ALDH 활성 및 ADH의 함량을 측정하였다. ALDH 활성은 알데하이드 탈수소효소(aldehyde dehydrogenase)활성 색도계(colorimetric) 어세이 키트(BioVision)를 이용하여 측정하였고, ADH는 알데하이드(aldehyde) 정량(quantification) 어세이 키트를 이용하여 측정하여 그 값을 하기 표 11에 나타냈다.In order to investigate the effect of the composition of the above example on the aldehyde dehydrogenase (ALDH) activity and the amount of acetaldehyde (AD) produced, the ALDH activity and the content of ADH were measured using the serum of the experimental animal obtained in Experimental Example 1. ALDH activity was measured using an aldehyde dehydrogenase activity colorimetric assay kit (BioVision), and ADH was measured using an aldehyde quantification assay kit, and the values are shown in the table below. It is shown in 11.
상기 표 11을 보면, 비교군에 비하여 실시예 투여군에서 알데하이드 탈수소효소의 활성은 월등히 높았으며, 아세트알데하이드 양도 현저하게 감소하여 우수한 효과를 보였다.As shown in Table 11, the activity of aldehyde dehydrogenase was significantly higher in the Example administration group than in the comparative group, and the amount of acetaldehyde was significantly reduced, showing excellent effects.
따라서, 본 발명의 조성물은 알코올 분해능이 우수함을 알 수 있었다.Therefore, it was found that the composition of the present invention has excellent alcohol resolution.
<숙취해소 효과 확인><Check the hangover relief effect>
본 발명의 조성물이 실제 음주 다음날 숙취를 해소하는지 확인하기 위해, 음주 후 본 발명의 조성물을 복용하게 하였다.In order to check whether the composition of the present invention actually relieves hangover the next day of drinking, the composition of the present invention was taken after drinking.
각 그룹당 건강한 20세 이상의 성인 남녀 10명을 대상으로 실험하였고, 실험을 위해 실험대상자들을 대상으로 소주 한잔 당 삼겹살 세 점을 먹도록 하여 300㎖의 소주를 60분에 걸쳐 마시도록 하였고, 음주 직후, 실시예의 조성물로 제조한 과립을 각각 4g씩 섭취하게 하였다. 비교군 1은 0.4ppm의 수소가 녹아 있는 수소수를 300㎖, 비교군 2는 시중에 판매되는 모닝케어 2병(200㎖)을 복용하도록 하였으며, 대조군으로는 생수 300㎖를 사용하였다. Each group was tested with 10 healthy men and women over 20 years of age, and for the experiment, subjects were asked to eat three pieces of samgyeopsal per glass of soju and drink 300 ml of soju over 60 minutes. Each of the granules prepared from the composition of the example was ingested by 4 g. Comparative group 1 was to take 300 ml of hydrogen water in which 0.4 ppm of hydrogen was dissolved, and comparative group 2 was to take two commercially available morning care bottles (200 ml), and 300 ml of mineral water was used as a control group.
이들 그룹이 다음날 아침에 확인한 숙취 제거효과, 소화 효과, 두통 정도에 대한 항목을, ‘효과 없음’을 1로 하고 ‘효과가 가장 높음’을 5로 하여, 5단계(1~5)의 범위 내로 작성하여, 하기 표 12에 나타냈다.The items on the hangover elimination effect, digestive effect, and headache degree checked by these groups the next morning were set to 1 for'no effect' and 5 for'highest effect', within the range of step 5 (1-5). Created and shown in Table 12 below.
상기 표 12를 참고하면, 본 발명에 따른 조성물을 복용한 경우가 매우 높은 숙취해소 효과를 보였다.Referring to Table 12, when taking the composition according to the present invention showed a very high hangover relief effect.
상술한 바와 같은 본 발명의 조성물은 간 손상 억제 효과가 있고, 간염 지수를 낮추어 각종 간질환을 예방 또는 치료할 수 있는 조성물로 이용이 가능하며, 알코올 분해 효과 및 아세트알데하이드 분해 효과가 매우 우수하고 음주 후 다음날의 두통, 구토증상 등을 완화하여 음주 전/후에 복용하는 간 보호 또는 숙취해소용 조성물로도 매우 유용하다. The composition of the present invention as described above has the effect of inhibiting liver damage, can be used as a composition that can prevent or treat various liver diseases by lowering the hepatitis index, and has excellent alcohol decomposition effect and acetaldehyde decomposition effect, and after drinking It is also very useful as a composition for protecting the liver or relieving hangovers taken before/after drinking by relieving headaches and vomiting symptoms the next day.
Claims (6)
금화규와 포포나무 잎 동일 중량비율 혼합물 열수 추출 동결 건조 분말: 및
수소 흡장 금속을 활성성분으로 포함하는 것으로 특징으로 하는 간 보호, 숙취해소 또는 알코올성 간 질환의 예방 또는 개선용 건강기능식품 조성물.
Green onion sprout hot water extract freeze-dried powder;
Freeze-dried powder extracted with hot water extracted with the same weight ratio of Geumhwagyu and Popo tree leaves: and
Health functional food composition for the prevention or improvement of liver protection, hangover relief or alcoholic liver disease, characterized in that it contains a hydrogen occlusion metal as an active ingredient.
The health functional food composition for preventing or improving liver protection, hangover relief, or alcoholic liver disease according to claim 1, wherein the hydrogen storage metal is magnesium hydride.
The method of claim 1 or 2, wherein when the hydrogen-occluding metal is 100 in a weight ratio, green onion sprout hot water extraction freeze-dried powder 150 to 200, and Geumhwagyu and Popola leaf same weight ratio mixture hot water extraction freeze-dried powder 150 to 200 Health functional food composition for the prevention or improvement of liver protection, hangover relief or alcoholic liver disease, characterized in that.
[3] The health functional food composition according to claim 1 or 2, wherein the composition further comprises vitamin C for preventing or improving liver protection, hangover relief, or alcoholic liver disease.
The method according to claim 4, wherein when the hydrogen-occluding metal is 100 in weight ratio, green onion sprout hot water extracted freeze-dried powder 150 to 200, Geumhwagyu and Popo tree leaf in the same weight ratio mixture hot water extracted freeze-dried powder 150 to 200, vitamin C 10 Health functional food composition for the prevention or improvement of liver protection, hangover relief or alcoholic liver disease, characterized in that to 20.
[3] The health functional food composition of claim 1 or 2, wherein the alcoholic liver disease is alcoholic hepatitis, alcoholic fatty liver or alcoholic liver cirrhosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190042302 | 2019-04-11 | ||
KR1020190042302 | 2019-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200120465A true KR20200120465A (en) | 2020-10-21 |
KR102299934B1 KR102299934B1 (en) | 2021-09-10 |
Family
ID=73034864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190099546A KR102299934B1 (en) | 2019-04-11 | 2019-08-14 | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102299934B1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102342437B1 (en) | 2021-05-04 | 2021-12-22 | 안동대학교 산학협력단 | Composition comprising extract of Hibiscus manihot for anti-obesity |
JP2022126128A (en) * | 2021-02-18 | 2022-08-30 | 株式会社日本トリム | Hydrogen water for prevention of alcoholic hepatopathy |
KR20220132164A (en) | 2021-03-23 | 2022-09-30 | 농업회사법인 이팜 주식회사 | Composition comprising extract of Hibiscus manihot for immune-enhancement |
KR20220164907A (en) * | 2021-06-07 | 2022-12-14 | 주식회사 알앤디테크 | Method for producing fruit Soju using Hibiscus manihot |
KR20220164909A (en) * | 2021-06-07 | 2022-12-14 | 주식회사 알앤디테크 | Method for producing collagen functional health alcoholic beverage |
KR20230079694A (en) | 2021-11-29 | 2023-06-07 | 안동대학교 산학협력단 | Functional companion animal feed composition comprising extract of Hibiscus manihot for anti-obesity |
KR20230092134A (en) | 2021-12-17 | 2023-06-26 | (주)옥천당 | Composition comprising low temperature water extract of Hibiscus manihot for anti-obesity |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020064151A (en) | 2001-01-31 | 2002-08-07 | (주)생명의나무 | Lower alcohol insoluble extract and a polysaccharide therein isolated from hovenia dulcis var. koreana nakai having antihepatotoxic and anti-hangover activity and composition containing same |
KR20020081995A (en) | 2001-04-23 | 2002-10-30 | (주)드리고 | Compound foods curing Hepato-toxicity and hangover, their formulations, and manufacturing methods |
KR100453575B1 (en) | 2001-07-09 | 2004-10-20 | 대한민국 | Food compositons derived from or containing crickets, exerting hepato-protective, antifatigue, enhancing activity of ethanol degradation, and inhibiting the formation of lipid-peroxidation |
KR100477957B1 (en) | 2001-04-13 | 2005-03-23 | 재단법인서울대학교산학협력재단 | Novel pyrrole derivatives isolated from lycium chinense mill having hepatoprotective activity and composition containing same |
KR100633851B1 (en) | 2004-04-22 | 2006-10-16 | 학교법인 상지학원 | Composition comprising the extract of heat-treated Allium victorialis L. var. platyphyllum for treating or preventing of liver disease or liver protection |
KR101106499B1 (en) | 2009-03-24 | 2012-01-20 | 장흥군 | Food composition with hepatoprotective effect containing the peduncle extracts of Hovenia dulcis Thunb |
KR101852840B1 (en) | 2018-01-02 | 2018-04-27 | 주식회사 한미양행 | Hepatoprotective composition comprising enzyme treated larva |
KR20200043088A (en) * | 2018-10-17 | 2020-04-27 | 주식회사 솔고 바이오메디칼 | Composition for for oral administration comprising hydrogen occlusion metal |
-
2019
- 2019-08-14 KR KR1020190099546A patent/KR102299934B1/en active IP Right Grant
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020064151A (en) | 2001-01-31 | 2002-08-07 | (주)생명의나무 | Lower alcohol insoluble extract and a polysaccharide therein isolated from hovenia dulcis var. koreana nakai having antihepatotoxic and anti-hangover activity and composition containing same |
KR100477957B1 (en) | 2001-04-13 | 2005-03-23 | 재단법인서울대학교산학협력재단 | Novel pyrrole derivatives isolated from lycium chinense mill having hepatoprotective activity and composition containing same |
KR20020081995A (en) | 2001-04-23 | 2002-10-30 | (주)드리고 | Compound foods curing Hepato-toxicity and hangover, their formulations, and manufacturing methods |
KR100453575B1 (en) | 2001-07-09 | 2004-10-20 | 대한민국 | Food compositons derived from or containing crickets, exerting hepato-protective, antifatigue, enhancing activity of ethanol degradation, and inhibiting the formation of lipid-peroxidation |
KR100633851B1 (en) | 2004-04-22 | 2006-10-16 | 학교법인 상지학원 | Composition comprising the extract of heat-treated Allium victorialis L. var. platyphyllum for treating or preventing of liver disease or liver protection |
KR101106499B1 (en) | 2009-03-24 | 2012-01-20 | 장흥군 | Food composition with hepatoprotective effect containing the peduncle extracts of Hovenia dulcis Thunb |
KR101852840B1 (en) | 2018-01-02 | 2018-04-27 | 주식회사 한미양행 | Hepatoprotective composition comprising enzyme treated larva |
KR20200043088A (en) * | 2018-10-17 | 2020-04-27 | 주식회사 솔고 바이오메디칼 | Composition for for oral administration comprising hydrogen occlusion metal |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022126128A (en) * | 2021-02-18 | 2022-08-30 | 株式会社日本トリム | Hydrogen water for prevention of alcoholic hepatopathy |
JP7308234B2 (en) | 2021-02-18 | 2023-07-13 | 株式会社日本トリム | Hydrogen water for suppressing alcoholic liver injury |
KR20220132164A (en) | 2021-03-23 | 2022-09-30 | 농업회사법인 이팜 주식회사 | Composition comprising extract of Hibiscus manihot for immune-enhancement |
KR102342437B1 (en) | 2021-05-04 | 2021-12-22 | 안동대학교 산학협력단 | Composition comprising extract of Hibiscus manihot for anti-obesity |
US11752187B2 (en) | 2021-05-04 | 2023-09-12 | Andong National University Industry-Academic Cooperation Foundation | Anti-obesity composition including Geumhwagyu extract as active ingredient |
KR20220164907A (en) * | 2021-06-07 | 2022-12-14 | 주식회사 알앤디테크 | Method for producing fruit Soju using Hibiscus manihot |
KR20220164909A (en) * | 2021-06-07 | 2022-12-14 | 주식회사 알앤디테크 | Method for producing collagen functional health alcoholic beverage |
KR20230079694A (en) | 2021-11-29 | 2023-06-07 | 안동대학교 산학협력단 | Functional companion animal feed composition comprising extract of Hibiscus manihot for anti-obesity |
KR20230092134A (en) | 2021-12-17 | 2023-06-26 | (주)옥천당 | Composition comprising low temperature water extract of Hibiscus manihot for anti-obesity |
US11864575B2 (en) | 2021-12-17 | 2024-01-09 | Andong National University Industry-Academic Cooperation Foundation | Composition comprising low temperature water extract of hibiscus manihot for anti-obesity |
Also Published As
Publication number | Publication date |
---|---|
KR102299934B1 (en) | 2021-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102299934B1 (en) | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution | |
KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
JP4669920B2 (en) | Functional material that suppresses blood glucose rise and blood pressure rise | |
CN109007808A (en) | A kind of relieving alcoholism and protecting liver composition and the relieving alcoholism and protecting liver preparation comprising it | |
KR101144059B1 (en) | Composition for prevention or treatment of diabete or obesity comprising Punica granatum extract and red ginseng extract | |
WO2020059995A1 (en) | Health drink composition for preventing liver damage caused by alcohol while providing excellent hangover relief | |
CN102697035A (en) | Cordyceps anti-aging pellet | |
KR100615039B1 (en) | Method of oriental herbal yogurt | |
KR101919839B1 (en) | Composition for hepatoprotective and ameliorating hangover containing cricket material enzyme-decomposed with Alcalase | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
KR101394358B1 (en) | Health composition relieving alcohol hangover | |
KR20120044807A (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
RU2274465C2 (en) | Anti-tumor and hypoglycemic compositions based on active components from basidiomycotina and araliaceae | |
KR20090081062A (en) | A diabetes pharmaceutical composition and manufacturing process thereof | |
JP3502072B2 (en) | Health food composition for protecting liver (Healthy food composition for protecting hepatic) | |
JP2005213211A (en) | Agent for inhibiting increase of blood glucose level | |
KR20170086198A (en) | Manufacturing method of diet solid tea including fermentation herb remedy and dietary fiber and the solid tea produced thereby | |
KR102433586B1 (en) | Food composition for relieving hangover and improving hepatic function | |
KR101399398B1 (en) | Method for manufacturing submerged-state fermented Allium victorialis and Composition for preventing or treating anti-diabetes or anti-diabetic complication containing fermented Allium victorialis | |
CN105597083B (en) | A kind of pair of liver kidney has health food of auxiliary protection function and preparation method thereof | |
KR100642801B1 (en) | Anti-diabetic food composition comprising extracts from natural herbal materials and pear and process for preparing the same | |
CN110876717A (en) | Preparation method of product capable of stabilizing blood sugar | |
Airaodion et al. | Chemical Composition and Nutraceutical Potential of Velvet Tamarind (Dialium guineense wild) Fruit Pulp | |
KR102203094B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
CN107647122A (en) | A kind of Chinese herbal composite feed additive for fattening beef cattle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |